Form 4 for JBIO Jade Biosciences, Inc.
Accepted 2023-05-03 00:00:00 ET · period of report 2023-05-01 · accession 0001415889-23-007247 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-05-03 | 2023-05-01+ | JBIO | NOYES TIMOTHY P | CEO, Dir | S - Sale+OE | $20.63 | -15.7K | 693 | -96% | -$323.8K |
| D | 2023-05-03 | 2023-05-01 | JBIO | NOYES TIMOTHY P | CEO, Dir | M - OptEx | $2.14 | +15.0K | 15.7K | +2,165% | +$32.1K |
| D | 2023-05-03 | 2023-05-01 | JBIO | NOYES TIMOTHY P | CEO, Dir | M - OptEx | $0.00 | -15.0K | 403.4K | -4% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-02 | S | D | 693 | $21.15 | 0 | D | — | — | (F2) Includes 693 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on April 30, 2023 in a transaction that is exempt under Rule 16b-3(c) and 16b-3(d). |
| 2 | Common | Common Stock | 2023-05-01 | S | D | 15,000 | $20.61 | 693 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.05 to $21.01, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. (F2) Includes 693 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on April 30, 2023 in a transaction that is exempt under Rule 16b-3(c) and 16b-3(d). |
| 3 | Common | Common Stock | 2023-05-01 | M | A | 15,000 | $2.14 | 15,693 | D | — | — | (F2) Includes 693 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on April 30, 2023 in a transaction that is exempt under Rule 16b-3(c) and 16b-3(d). |
| 4 | Derivative | Stock Option (Right to Buy) | 2023-05-01 | M | D | 15,000 | $0.00 | 403,381 | D | $2.14 · — to 2031-04-01 | 15,000 Common Stock | (F4) A total of 493,381 shares subject to an employee stock option were granted on April 2, 2021, with 25% vested on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter. |